High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. - Wikidata - wikimedia - TriplyDB

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.

http://www.wikidata.org/entity/Q30433183

about

Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Systems biology approaches for advancing the discovery of effective drug combinations Synergy Maps: exploring compound combinations using network-based visualization Approaches to modernize the combination drug development paradigm Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of Assays Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs Discovery of Drug Synergies in Gastric Cancer Cells Predicted by Logical Modeling Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins.A High-Throughput Screen Identifies 2,9-Diazaspiro[5.5]Undecanes as Inducers of the Endoplasmic Reticulum Stress Response with Cytotoxic Activity in 3D Glioma Cell Models Applications of chemogenomic library screening in drug discovery Current approaches for the discovery of drugs that deter substance and drug abuse.The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine.Large-scale pharmacological profiling of 3D tumor models of cancer cells.High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations Characteristics of drug combination therapy in oncology by analyzing clinical trial data on ClinicalTrials.gov.A high-throughput assay for small molecule destabilizers of the KRAS oncoprotein Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation Ibrutinib treatment of CLL: the cancer fights back.Immunohistochemical algorithm alone is not enough for predicting the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP B-cell receptor signaling in diffuse large B-cell lymphoma.DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling and tumor cell survival in diffuse large B cell lymphoma Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia.Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic Implications.Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma A novel quantitative high-throughput screen identifies drugs that both activate SUMO conjugation via the inhibition of microRNAs 182 and 183 and facilitate neuroprotection in a model of oxygen and glucose deprivation.Multiplexed barcoded CRISPR-Cas9 screening enabled by CombiGEM.Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer.Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm.SynergyFinder: a web application for analyzing drug combination dose-response matrix data.Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.

P2860

Q26744277-0CB64C8F-90F2-4B33-A3CF-D245451ABFD7 Q26784108-6AE92878-C658-4D4D-8A5F-114723F033E6 Q26801410-44A64019-FA9C-4C04-A7CF-FEB83E07E46F Q27304386-B007F449-3AEC-4FC6-853C-F0BB210FBBAD Q27702922-E1D39CCA-A9AD-4C5F-9BFF-12F6AB8A1ACD Q27902355-5B067865-9CE4-4249-8D61-C740C29ED723 Q28072074-AA1B7BD6-B292-4533-BCB6-ADA2A5FC128A Q28115962-BB3145DC-6F51-42DA-B4FE-21DE7AFFDCB4 Q28546583-8FCCF846-6AA9-44D0-891E-A85127DBFF0A Q28547522-20519C59-8AFC-4318-A6FD-3AA24669C5AC Q28547862-55ACEEF9-6D5C-421C-8FEC-B164B603E320 Q28548425-70C133C9-4233-46FC-9970-2DDB519D0B23 Q28553712-5B02F7CA-F0A5-4CAA-B15E-858E14F2597E Q28553753-2550A9F4-31F4-4872-89C6-23C881B0FBAA Q28656335-69F049BC-A1C4-4236-B5F5-B30542713660 Q28973615-2D5857CF-C5C4-4215-ADF3-8BF5FB15BBAD Q30252649-6B748A02-AF6B-4D2D-91E3-51C1722CC3E3 Q30279055-8ED698F6-B856-4F3E-9F27-A402489B8493 Q30364972-80F061A3-4C7A-429C-81DB-1524669A1C4B Q30402235-2A7DE1FE-E48D-4A75-AB78-952FE43D24CD Q30884583-B2439CEC-2F01-4E13-986E-01C62BED399B Q34004748-7FA75E82-BB28-470C-B00F-C32199010BD5 Q34025327-740BE555-06EE-48E0-A7DB-947F41F5E232 Q34104112-30B4EB29-9C5A-41E1-A792-E2CA5D156D0E Q34325329-C29E854F-F6C9-4D85-B2CE-36144880552F Q34352273-DD54DA69-8E31-434F-B3C4-B69186CAF68B Q35145270-2E520AF2-0DCF-4FAC-80C4-0ADCC50C3464 Q35218042-4894A49E-EB89-4A34-BD36-CB7C1D8ACC6E Q35568457-319A51A7-7DDC-4A07-B978-6C65BC57E886 Q35671227-8D33C303-FD0A-4F74-BCA8-9FA08BEF54B7 Q35818443-18754B97-691B-4288-9A0C-181D39EB2562 Q35819646-D0E800CA-1CF0-4A16-B477-C1875608C2E6 Q35867650-25CB8D45-60E2-430D-91F4-CC9775262FFE Q35920105-1DAB94DD-4E7A-46A0-AD3F-25843B8E802A Q35958056-6D165D7C-D00C-40CD-AB9B-BBC3A721A3B2 Q36139333-4EC2D99E-AB77-48DB-8BEA-CC200BF0F60A Q36155080-ADDB5579-59BA-4D3D-80A8-089C5233EFDD Q36193086-5F31CF5E-4360-4FD5-8E0C-ADA0E45AF652 Q36335514-A8412D1F-2367-431B-8288-7047BE85FDD3 Q36335846-DFA15094-0E9F-4663-9910-31B1EF9A8AC3

P2860

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.

http://www.wikidata.org/entity/Q30433183

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

High-throughput combinatorial ...... e large B-cell lymphoma cells.

@ast

High-throughput combinatorial ...... e large B-cell lymphoma cells.

@en

type

label

High-throughput combinatorial ...... e large B-cell lymphoma cells.

@ast

High-throughput combinatorial ...... e large B-cell lymphoma cells.

@en

prefLabel

High-throughput combinatorial ...... e large B-cell lymphoma cells.

@ast

High-throughput combinatorial ...... e large B-cell lymphoma cells.

@en

P1433

Q30433183-873A367B-1FE4-4179-B668-4DF92DC11334

P1476

Q30433183-9072F1A2-DAE0-43CC-83C6-904E8E2A422C

P2093

Q30433183-00F02B29-582E-4534-BC40-45E001362837

Q30433183-137BF3DA-ECAD-48B0-BAD2-4F47774149AE

Q30433183-1A198195-717F-4230-A8A6-229DFE1F7726

Q30433183-1FF9CB65-7163-4559-8F48-A24E73EEC0AB

Q30433183-2B0EFDEE-7974-4620-90C2-0715885695A5

Q30433183-382C7BD0-F702-4FBC-9A45-E042EEA50270

Q30433183-3B27E805-177B-40EE-89C6-74AF7975A7DD

Q30433183-3E7F1606-F43D-4B79-9C03-2417F2DE6D34

Q30433183-3E8ED058-7503-443C-843A-7E9F726EC494

Q30433183-5BB2FC3C-E431-408F-963D-DED18D6A1759

P2860

Q30433183-0681D9C4-64EA-4E37-8941-873D66408BB8

Q30433183-17468599-91B6-4CEE-BB9F-F22FFDF6E180

Q30433183-18331547-C312-40A5-9DE7-4B67B52C241B

Q30433183-1C3D937F-E8C4-45BC-AEC8-94272FACE1A3

Q30433183-1D12B46D-1D58-442B-8D6E-19C4C1CD2738

Q30433183-1E013E6D-2F1A-4695-B726-6A040AAC8FE7

Q30433183-22839362-665D-42F0-BBC7-28E09E69B33B

Q30433183-26C16651-43FE-4D71-8B71-47B28093CC0E

Q30433183-27F141B7-E72B-444D-B679-51B5EF2C6DDB

Q30433183-2D3D0490-C518-4839-BB4C-53ABD507B813

P304

Q30433183-F29D0CB0-7D9A-468A-B3A2-B37159AB056E

P31

Q30433183-DA70106F-24CC-4625-97F0-10E43C4D3EC6

P356

Q30433183-593935F5-5BA4-4489-B794-60850F804697

P407

Q30433183-E4950249-21C8-4F90-9561-C29F74E8D058

P433

Q30433183-75E07A0B-357E-4F05-BF78-6C9D91305EF7

P478

Q30433183-E58BEF68-A358-438F-8737-9301684FFABD

P50

Q30433183-66230E42-43A1-42FC-A3D2-08761FBEE350

Q30433183-9AF0C546-2116-4EAD-9D9B-A43FA18E902C

Q30433183-BD26FC42-DAD4-42DB-A154-1934CE53DCDB

Q30433183-BEBEA44E-44C1-4AA4-8B59-B7558BB097AB

Q30433183-D1143EDB-B287-4ACF-A253-9A31E7DE152A

Q30433183-DB6A9E9D-5D93-4631-A271-E2BABA9EDF61

P577

Q30433183-BAA5C8F9-592C-42CA-926F-BA712F6554D1

P5875

Q30433183-1B7DFA62-B0EE-4495-A321-29FAEBA06360

P698

Q30433183-45D4EDF5-6101-4933-8FB7-8A0EAD906921

P921

Q30433183-59E69E89-8725-4AF8-8C1D-8DAB2B17A9B4

P932

Q30433183-E09064BA-1E5B-4A8A-9247-D1A324AF18D2

P356

PNAS.1311846111

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

High-throughput combinatorial ...... e large B-cell lymphoma cells.

@en

P2093

Christopher A Leclair

http://www.w3.org/2001/XMLSchema#string

Craig J Thomas

http://www.w3.org/2001/XMLSchema#string

Crystal McKnight

http://www.w3.org/2001/XMLSchema#string

Damien Y Duveau

http://www.w3.org/2001/XMLSchema#string

David J Maloney

http://www.w3.org/2001/XMLSchema#string

Dongbo Liu

http://www.w3.org/2001/XMLSchema#string

Ganesha Rai

http://www.w3.org/2001/XMLSchema#string

Ian S Goldlust

http://www.w3.org/2001/XMLSchema#string

Jian-Kang Jiang

http://www.w3.org/2001/XMLSchema#string

Jonathan M Keller

http://www.w3.org/2001/XMLSchema#string

P2860

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Efficient discovery of anti-inflammatory small-molecule combinations using evolutionary computing

Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action

Oncogenically active MYD88 mutations in human lymphoma

Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma

P304

2349-2354

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1311846111

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

Christopher P Austin

P577

2014-01-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259956709

http://www.w3.org/2001/XMLSchema#string

P698

24469833

http://www.w3.org/2001/XMLSchema#string

P921

P932

3926026

http://www.w3.org/2001/XMLSchema#string